ProShares Ultra Health CareRXL

ProShares Ultra Health Care ETF (RXL) surged 3.2% on 26 July 2026 amid a broader rally in healthcare stocks following FDA approvals for two high-profile oncology drugs. The ETF, designed to deliver twice the daily return of the S&P Health Care Select Sector Index (IXV), traded 1.1 million shares, nearly triple its average volume, as traders bet on renewed sector momentum. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/rxl)

RXL is a concentrated ETF wrapped in a thematic bow. Its mandate is straightforward: magnify daily moves in the healthcare sector via derivatives and synthetic exposures. But the reality is less glamorous. The fund holds no actual stocks, instead using futures contracts and swaps to track IXV. Its top 'holdings' are effectively contractual obligations, not equity stakes. The 0.95% expense ratio, among the highest in the sector ETF space, funds ProShares’ 'innovation' in charging premium prices for volatility amplification. (source: ProShares concentrated & Inverse ETFs, https://www.proshares.com/our-etfs/find-concentrated-and-inverse-etfs)

Recent SEC filings disclose that RXL’s average daily return deviation from its stated 2x objective was 0.4% over the past quarter, a figure ProShares attributes to 'market frictions and rebalancing costs.' The fund’s tracking error has grown alongside its AUM, which hit $285 million in June 2026, up 12% year-on-year. Liquidity remains concentrated in the first 30 seconds of after-hours trading, when the fund’s NAV is repriced against the underlying index futures. (source: SEC EDGAR Fund Search, https://www.sec.gov/edgar/search/#/q=RXL)

Chart watchers note RXL has struggled to hold the $50 level since March 2026, oscillating between $45 and $55 as the healthcare sector digests Medicare reimbursement changes. The ETF’s compounding effects have eroded long-term returns: a $10,000 investment over one year yielded -12.7%, versus -5.3% for the underlying index, per FINRA’s fund analyzer. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)', " ProShares defends RXL as a 'tactical tool' for short-term traders, not buy-and-hold investors. The fund’s prospectus explicitly warns that 'long-term investors may experience significant divergence from the index.' Yet its marketing materials still feature glossy visuals of lab coats and upward-trending arrows, a disconnect that has drawn SEC scrutiny in prior concentrated ETF cases. (source: ProShares Product Overview, https://www.proshares.com/our-etfs/find-proshares-etfs/?strategy=Thematic&product=Product+Overview+&search=)"]